_:n4c4215832d534ac9a92f7f97275e5921xb0
<http://schema.org/description>
"The PANORAMA trial showed that by 1 year, 20% of untreated patients developed proliferative diabetic eye disease, and aflibercept injection reduced this risk by 85% to 88% when administered using an every 16-week or eight-week dosing regimen, respectively."
<https://www.contemporaryclinic.com/view/aflibercept-for-diabetic-retinopathy-receives-fda-approval>